Answers are grounded in this paper and cite their sources.
Importance Low mobility is common during an acute hospitalization and is associated with adverse outcomes, such as loss of independence and death. Previous interventions that were successful in increasing hospital mobility required resources that are not available in everyday clinical practice, limiting their scalability. Objective To assess whether the theory-informed Intervention to Increase Mobility in Older Hospitalized Medical Patients (INTOMOB) improves life-space mobility at 30 days in older hospitalized medical patients. Design, Setting, and Participants This is a multicenter, parallel, partially blinded, cluster randomized clinical superiority trial, with randomization at the hospital ward level and 180-day follow-up. Patients were recruited between October 2023 and January 2025 at acute general internal medicine wards of 3 Swiss hospitals. Main eligibility criteria were age 60 years or older, living in the community, and planned hospital stay 3 or more days. Intervention The intervention was compared with standard of care and included booklets and videos for patients, health care professional training, and posters in the wards. Main Outcomes and Measures The primary outcome was life-space mobility at 30 days, a measure of how far and often a person moves within their environment, from bedroom to beyond their town (range, 0-120 points, with higher scores denoting greater mobility). Secondary outcomes included physical activity during hospitalization, new institutionalizations (ie, transition to nursing home), and quality of life. For time-to-event outcomes, Cox models with cluster-robust SEs were used. Multinomial logistic regression with robust SEs was used for categorical outcomes. Results Of 1334 eligible patients, 383 (median [IQR] age, 75 [68 to 81] years; 234 male [61.1%]) agreed to participate and were randomized to 12 clusters (183 patients [47.8%] in the intervention group and 200 patients [52.2%] in the control group). The primary outcome was available for 327 patients (85.4%). The median (IQR) length of stay was 5 (3 to 7) days. Life-space mobility at 30 days was not significantly different between control and intervention groups (adjusted difference, 0.67 points; 95% CI, −4.35 to 5.68 points). There were no serious adverse events potentially related to the intervention. There was no consistent statistically significant difference in any other secondary outcomes. Conclusions and Relevance The INTOMOB intervention did not result in a significantly improved short-term life-space mobility or other clinical outcomes. However, the feasibility of the INTOMOB intervention provides a foundation for future mobility interventions aiming to improve both effectiveness and applicability in everyday clinical practice. Trial Registration ClinicalTrials.
No takes yet. Share an insight, caveat, or question.
Schiffmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: